This review therefore focuses on the emerging WNT11/CAMKII axis as a newly identified immune resistance pathway in liver metastasis, and discusses its mechanistic roles, clinical implications, and therapeutic potential in reshaping the metastatic tumor microenvironment. This evidence concerns the gene WNT11 and neoplasm.